Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) trades at $26.82. Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) focuses on investing in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares). Market cap: $2.40M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for NVOH: NVOH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NVOH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NVOH: 1/1 perspectives are bearish.
How is this calculated? →Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) Healthcare & Pipeline Overview
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged is a non-diversified fund investing primarily in ADRs of Novo Nordisk A/S, a leading global healthcare company focused on diabetes care and other serious chronic diseases. The fund provides investors exposure to Novo Nordisk's performance through ADRs.
What Is the Investment Thesis for NVOH?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) offers a focused investment opportunity tied directly to the performance of Novo Nordisk A/S, a leader in diabetes care and other chronic diseases. The fund's value is intrinsically linked to Novo Nordisk's ability to maintain its market position, innovate in its core therapeutic areas, and expand into new markets. Key value drivers include Novo Nordisk's pipeline of new drugs, its ability to navigate regulatory landscapes, and its success in managing competition from biosimilars. The fund's non-diversified nature concentrates risk, making it sensitive to any adverse events affecting Novo Nordisk, such as clinical trial failures or significant patent expirations. Investors may want to evaluate Novo Nordisk's growth prospects, particularly in emerging markets, and its ongoing efforts to diversify its product portfolio beyond insulin. The fund's beta of 1.94 suggests higher volatility compared to the broader market.
Based on FMP financials and quantitative analysis
NVOH Key Highlights
- NVOH invests at least 95% of its net assets in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares), providing focused exposure.
- The fund is non-diversified, meaning its performance is highly dependent on the success of a single company, Novo Nordisk A/S.
- Novo Nordisk A/S is a global healthcare company specializing in diabetes care and other serious chronic diseases.
- NVOH's performance is directly linked to Novo Nordisk's ability to innovate, maintain market share, and navigate regulatory challenges.
- The fund's beta of 1.94 indicates higher volatility compared to the overall market.
Who Are NVOH's Competitors?
NVOH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVOH's Key Strengths?
- Focused investment strategy.
- Exposure to a leading global healthcare company.
- Potential for high returns based on Novo Nordisk's performance.
What Are NVOH's Weaknesses?
- Non-diversified nature increases risk.
- Performance is entirely dependent on a single company.
- Susceptible to regulatory and market risks affecting Novo Nordisk.
What Could Drive NVOH Stock Higher?
- Clinical trial results for Novo Nordisk's new drug candidates.
- Regulatory approvals for Novo Nordisk's products in key markets.
- Expansion of Novo Nordisk's market share in diabetes care and obesity treatment.
- Strategic partnerships and acquisitions by Novo Nordisk to expand its portfolio.
What Are the Key Risks for NVOH?
- Patent expirations and biosimilar competition affecting Novo Nordisk's revenue.
- Regulatory setbacks or adverse clinical trial results for Novo Nordisk's products.
- Economic downturns impacting healthcare spending and pharmaceutical sales.
- Dependence on a single company (Novo Nordisk) for fund performance.
- Market volatility affecting the value of Novo Nordisk's shares.
What Are the Growth Opportunities for NVOH?
- Expansion in Emerging Markets: Novo Nordisk has significant growth potential in emerging markets, where the prevalence of diabetes is rapidly increasing. These markets offer a large and relatively untapped patient base. Success in these regions could drive substantial revenue growth for Novo Nordisk, positively impacting NVOH's value. The timeline for realizing this growth is ongoing, with continuous expansion efforts expected over the next 5-10 years. The market size is estimated to be worth billions of dollars annually.
- Innovation in Diabetes Care: Novo Nordisk's ongoing research and development efforts in diabetes care, including the development of new insulin formulations and delivery systems, represent a significant growth opportunity. The successful launch of innovative products could strengthen Novo Nordisk's market position and drive revenue growth. This is an ongoing process, with new products expected to be launched regularly. The diabetes care market is projected to grow steadily.
- Diversification into Obesity Treatment: Novo Nordisk's expansion into obesity treatment represents a significant growth opportunity, addressing a large and growing market. Successful development and commercialization of obesity drugs could diversify Novo Nordisk's revenue streams and reduce its reliance on diabetes care. This is an ongoing effort with potential for significant impact over the next 3-5 years. The obesity treatment market is estimated to be worth billions of dollars.
- Strategic Partnerships and Acquisitions: Novo Nordisk can pursue strategic partnerships and acquisitions to expand its product portfolio and geographic reach. These collaborations can provide access to new technologies, markets, and expertise, driving long-term growth. The timeline for such partnerships is unpredictable, but they represent a continuous opportunity. The impact on market size depends on the specific partnerships.
- Advancements in Digital Health Solutions: Novo Nordisk is exploring digital health solutions to improve diabetes management and patient outcomes. These solutions include mobile apps, wearable devices, and data analytics platforms. Successful integration of digital health into its offerings could enhance patient engagement and drive revenue growth. This is an ongoing area of development with potential for significant impact over the next 3-5 years. The digital health market is rapidly expanding.
What Opportunities Does NVOH Have?
- Growth in the diabetes care and obesity treatment markets.
- Expansion of Novo Nordisk into new geographic regions.
- Innovation in pharmaceutical products and delivery systems.
What Threats Does NVOH Face?
- Competition from other pharmaceutical companies.
- Patent expirations and biosimilar competition.
- Regulatory changes and healthcare policy shifts.
- Adverse events affecting Novo Nordisk's operations or reputation.
What Are NVOH's Competitive Advantages?
- Focused investment strategy providing unique exposure to Novo Nordisk A/S.
- Access to Novo Nordisk's growth and innovation in the diabetes care market.
- ADR structure simplifies investment for US-based investors.
What Does NVOH Do?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) is a specialized investment vehicle designed to provide investors with exposure to Novo Nordisk A/S (B Shares) through American Depositary Receipts (ADRs). Established to offer a targeted investment strategy, the fund operates under the Precidian ETFs Trust umbrella, focusing exclusively on Novo Nordisk ADRs. The fund invests at least 95% of its net assets in these ADRs, making it a highly concentrated investment. Unlike diversified funds, NVOH does not spread its investments across multiple companies or sectors, instead, it is specifically linked to the performance of Novo Nordisk A/S. Novo Nordisk A/S, the underlying company, is a global healthcare leader headquartered in Bagsværd, Denmark. It is renowned for its pioneering work in diabetes care, as well as its contributions to the treatment of other serious chronic conditions such as obesity, hemophilia, and growth disorders. Novo Nordisk's history is rooted in the discovery of insulin in 1923, and since then, the company has been at the forefront of developing innovative pharmaceutical products and delivery systems. NVOH offers investors a way to participate in the financial performance of Novo Nordisk without directly purchasing the company's shares on the Copenhagen Stock Exchange. The fund's performance is therefore closely tied to the success and strategic direction of Novo Nordisk A/S in the global pharmaceutical market.
What Products and Services Does NVOH Offer?
- Invests primarily in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares).
- Provides investors with exposure to the financial performance of Novo Nordisk A/S.
- Operates as a non-diversified fund, concentrating its investments in a single company.
- Offers a targeted investment strategy focused on the healthcare sector.
- Tracks the performance of Novo Nordisk A/S in the global pharmaceutical market.
- Allows investors to participate in Novo Nordisk's growth without directly purchasing its shares.
How Does NVOH Make Money?
- Generates revenue through investment in Novo Nordisk A/S ADRs.
- Fund performance is directly tied to the market value of Novo Nordisk's shares.
- Manages assets on behalf of investors seeking exposure to Novo Nordisk.
What Industry Does NVOH Operate In?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged operates within the healthcare sector, specifically the pharmaceutical industry. This sector is characterized by high research and development costs, stringent regulatory oversight, and intense competition. The global pharmaceutical market is projected to reach trillions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. NVOH's success depends heavily on Novo Nordisk's ability to compete effectively in this landscape, particularly in the diabetes care market, where it holds a significant position. Competitors include other major pharmaceutical companies developing and marketing diabetes treatments and related therapies.
Who Are NVOH's Key Customers?
- Institutional investors seeking exposure to Novo Nordisk A/S.
- Retail investors interested in the healthcare sector and pharmaceutical industry.
- Investors looking for a targeted investment strategy focused on a single company.
NVOH Financials
Bull Case vs Bear Case
Bull Case
- Focused investment strategy.
- Exposure to a leading global healthcare company.
- Potential for high returns based on Novo Nordisk's performance.
- Upcoming: Clinical trial results for Novo Nordisk's new drug candidates.
Bear Case
- Non-diversified nature increases risk.
- Performance is entirely dependent on a single company.
- Susceptible to regulatory and market risks affecting Novo Nordisk.
- Potential: Patent expirations and biosimilar competition affecting Novo Nordisk's revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NVOH Latest News
No recent news available for NVOH.
NVOH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVOH.
Price Targets
Wall Street price target analysis for NVOH.
NVOH MoonshotScore
What does this score mean?
The MoonshotScore rates NVOH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
What Investors Ask About Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) — Healthcare
What does Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged do?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) is a fund that invests primarily in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares). This means the fund's performance is directly linked to the success of Novo Nordisk, a global healthcare company specializing in diabetes care and other serious chronic diseases. By investing in NVOH, investors gain exposure to Novo Nordisk's financial performance without directly purchasing the company's shares on the Copenhagen Stock Exchange. The fund is non-diversified, concentrating its investments solely in Novo Nordisk ADRs.
What do analysts say about NVOH stock?
As of 2026-03-17, AI analysis for NVOH is pending. However, the fund's performance is intrinsically tied to the performance of Novo Nordisk A/S. Analysts covering Novo Nordisk typically focus on the company's revenue growth, pipeline developments, and market share in the diabetes care and obesity treatment markets. Key valuation metrics include price-to-earnings ratio and enterprise value-to-EBITDA. Investors should monitor analyst reports on Novo Nordisk to assess the potential risks and rewards associated with NVOH.
What are the main risks for NVOH?
The primary risk associated with Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged is its non-diversified nature. Because the fund invests almost exclusively in Novo Nordisk ADRs, its performance is entirely dependent on the success of a single company. Risks specific to Novo Nordisk include patent expirations, competition from biosimilars, regulatory challenges, and adverse clinical trial results. Additionally, broader market risks and economic downturns could impact the value of Novo Nordisk's shares and, consequently, the fund's performance. Investors should carefully consider these risks before investing in NVOH.
What are the key factors to evaluate for NVOH?
Evaluate NVOH on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NVOH data refresh on this page?
NVOH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NVOH's recent stock price performance?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused investment strategy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NVOH overvalued or undervalued right now?
Valuing Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NVOH?
Before investing in Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for NVOH. Information is based on available data and may be subject to change.
- The fund's performance is highly dependent on the performance of Novo Nordisk A/S.